A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have added about 12% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Loss Narrower-Than-Expected, Sa ...